Mintz Levin is hosting a three-part series focused on financing for life sciences companies from initial funding to IPO via private sources, non-traditional IPOs, and traditional IPOs. Mintz Levin attorneys, Jeremy Glaser and Bill Whelan, will be joined by Barbara McClung, Chief Legal Officer and Corporate Secretary, Caribou Biosciences and Mark Lappe, CEO, INHIBRx to share insights into the private capital raising process.
Our first session will focus on financing sources for private life sciences, medical device, medical technology, and health IT companies, including angel funding, joint development, strategic investors, and venture capital. A panel of entrepreneurs, in-house counsel, and advisors will share best practices and practical considerations to prepare companies for raising their first, or next, round of capital, including:
- Best practices for raising capital, including important legal considerations
Common legal pitfalls and how to avoid them
What to expect and plan for at each stage of funding
Negotiating and drafting term sheets
CEOs, CFOs, in-house counsel, and service providers will benefit from this discussion of current best practices and trends.
Please also join us for Parts 2 & 3!
Tuesday, May 9, 2017: Going Public Through a Non-Traditional IPO
Tuesday, September 12, 2017: Going Public through a Traditional IPO
All seminars will be held in Mintz Levin's San Diego Office.